Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Recall on Single Lot of Barr Laboratories Brand Dextroamphetamine/Amphetamine 20mg Tablets
Barr Laboratories, Inc. has recalled a single lot of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate (mixed amphetamine salts) 20mg tablets. The lot number involved in the recall is lot number 311756. The affected lot was available to patients after June 11, 2009. These tablets may be oversized and contain more drug than appropriate. This could result in patients receiving more than the expected dosage of this drug. Dextroamphetamine/Amphetamine is used in the treatment of narcolepsy and attention deficit disorder and is also known by the brand names Adderall and Adderall XR. However, Barr Laboratories lot number 311756 is the only lot involved and no other lot numbers, strengths, or brands of Dextroamphetamine/Amphetamine are affected by this recall. For more information, please visit: http://www.fda.gov/Safety/Recalls/ucm177321.htm
Learn More

Cases of Anemia Reported in Patients Treated with CellCept
Roche notified healthcare professionals that cases of Pure Red Cell Aplasia (PRCA) have been reported in patients treated with CellCept (mycophenolate mofetil) in combination with other immunosuppressive agents. Pure Red Cell Aplasia is a type of anemia where the bone marrow slows or stops production of red blood cells. The WARNINGS and ADVERSE REACTIONS sections of the CellCept Prescribing Information have been revised to reflect this new safety information. For more information, please visit: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm177397.htm
Learn More

Date Published Title Drug Source
2009-08-14 Recall on Single Lot of Barr Laboratories Brand Dextroamphetamine/Amphetamine 20mg Tablets Amphetamine Salts FDA
2009-08-14 Cases of Anemia Reported in Patients Treated with CellCept Mycophenolate Manufacturer
2009-08-21 FDA Sends Warning Letters to Marketers of Topical Ibuprofen Products Ibuprofen FDA
2009-08-21 King Pharmaceuticals To Stop Making Intal Inhalers Cromolyn Sodium Manufacturer
2009-08-21 Discontinuation of Lilly Humulin 50/50 and Select NovoNordisk Insulin Delivery Devices Insulin Manufacturer
2009-08-21 Recall of One Lot of Fenoglide Samples Fenofibrate FDA
2009-08-21 Recall of Single Lot of Mucinex DM Tussin DM FDA
2009-08-21 Discontinuation of Lilly Humulin 50/50 and Select NovoNordisk Insulin Delivery Devices FDA
2009-08-21 Discontinuation of Lilly Humulin 50/50 and Select NovoNordisk Insulin Delivery Devices NPH Insulin Manufacturer
2009-08-24 Early Communication about an Ongoing Safety Review for Orlistat (marketed as Alli and Xenical) Orlistat FDA
2009-08-25 Two Lots of Advair Diskus Reported Stolen Fluticasone Propionate with Salmeterol FDA
2009-08-26 Recall of Two lots of Accusure Insulin Syringes Insulin FDA
2009-08-26 Recall of Two Lots of Accusure Insulin Syringes Insulin Glargine FDA
2009-08-26 Recall of Two Lots of Accusure Insulin Syringes Insulin Aspart FDA
2009-08-26 Recall of Two Lots of Accusure Insulin Syringes Insulin Detemir FDA
2009-08-26 Recall of Two Lots of Accusure Insulin Syringes Insulin Lispro FDA
2009-08-27 Reminder Alert: Three Lots of Levemir Insulin Reported Stolen Insulin Detemir FDA
2009-08-27 Tamsulosin (Flomax) Linked to Serious Eye Complications Following Cataract Surgery Tamsulosin MediGuard CRT
2009-08-27 Two Recent Studies Support Safety Concerns of Erythropoiesis Stimulating Agent Use in Cancer Patient Epoetin Alfa MediGuard CRT
2009-08-27 Two Recent Studies Support Safety Concerns of Erythropoiesis Stimulating Agent Use in Cancer Patient Darbepoetin Alfa MediGuard CRT